Nucleic acid medicine platform technology - hetero double-stranded nucleic acid (HDO)
Catalog Presentation: HDO Technology, which is expected to improve enzyme resistance in the bloodstream and reduce toxicity.
Our company handles "Hetero Double-Stranded Nucleic Acid (HDO)," which can selectively deliver active strands to disease sites by binding ligands to carrier strands, thereby expecting high therapeutic efficacy. HDO has a double-stranded structure, making it inherently stable. It avoids chemical modifications to the active strand, which can reduce toxicity. 【Features】 ■ Selectively delivers active strands to disease sites, achieving high therapeutic efficacy ■ Avoids chemical modifications and reduces toxicity ■ Provides a structurally stable material, improving enzyme resistance in the bloodstream ■ Low likelihood of unexpected therapeutic effects ■ Allows for free selection of the position and number of ligands binding to the carrier strand ■ The HDO technology is licensed to Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals (USA), Nippon Shokubai Co., Ltd., and Nippon Gene Material Co., Ltd. ■ The HDO technology is covered by multiple registered patents, ensuring safe use. ■ Collaborative research using HDO technology for drug discovery can also be conducted with our company. *For more details, please download the PDF or contact us.
- Company：レナセラピューティクス
- Price：Other
